Ronald P Mischak

Title: The Innovative Contributions of Ronald P Mischak

Introduction

Ronald P Mischak is a notable inventor based in Palo Alto, CA, who has made significant contributions to the field of cancer therapy and neurobiology. With a total of 7 patents to his name, his work focuses on developing novel therapeutic approaches to combat serious health conditions.

Latest Patents

One of his latest patents is titled "Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy." This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents. These combinations can be used to treat a mammalian host, usually a human, suspected of having cancer or tumor cells by administering the combination in a therapeutically- or synergistically-effective amount. The drug combinations cytotoxic to tumor cells comprise an anti-neoplastic agent and a molecule that binds the tumor cells and induces an increase in the phosphorylation of c-erbB-2 protein when placed in contact with the tumor cells. Alternatively, the drug combination may comprise an anti-neoplastic agent and a molecule that causes down modulation or internalization of c-erbB-2 protein. The anti-neoplastic drug is preferably an alkylating agent, most preferably cisplatin, and this combination is particularly effective for inhibiting the growth of breast and ovarian tumor cells. Methods for killing target tumor cells are contemplated by contacting the target cells with the novel drug combinations, and methods for treating mammals by administering therapeutic amounts of the drug combinations are also included.

Another significant patent involves "Assays for β-amyloid processing." This invention relates to the design, construction, and use of eukaryotic cell lines useful in identifying inhibitors of β-amyloid processing. More specifically, it includes in vitro assays capable of identifying or quantifying a 4.2 kDa β-amyloid protein. The present invention also provides for DNA and protein molecules for the design, construction, and use of eukaryotic cell lines useful in the identification of inhibitors of β-amyloid processing.

Career Highlights

Throughout his career, Ronald has worked with prominent companies such as Scios Inc. and Berlex Laboratories, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions in the medical field.

Collaborations

Ron